Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Incorrect dosing can lead to inadequate glycaemic control or increased risk of adverse effects
Unlike existing approved therapies, it simultaneously targets GLP-1, GIP, and glucagon receptors, a mechanism that early clinical data suggest may produce substantial metabolic effects
Consider that the list prices of a years supply of approved GLP-1s exceed: $11,000 for Ozempic, the formulation of semaglutide approved for Type 2 diabetes $16,000 for Wegovy, the formulation approved as a weight-loss treatment $12,000 for Mounjaro and Zepbound, the formulations of tirzepatide approved for Type 2 diabetes and for weight loss, respectively Manufacturers savings programs and pharmacy discounts may reduce those prices
Preclinical rodent models show similar effects through combined appetite suppression, increased energy expenditure, and enhanced lipid oxidation
US$ 25.56
US$ 25.81
US$ 26.59
US$ 26.06
US$ 27.04
US$ 20.00
